Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.
She has an MA in business and economic reporting from New York University. You can connect with Laura on LinkedIn or Twitter.
New Data Challenge Traditional Treatment Paradigm in MPNs, Says Dr Raajit Rampal
April 20th 2024Traditionally, low-risk patients with myeloproliferative neoplasms (MPNs) are not given medication, but new data challenge that thinking, said Raajit Rampal, MD, PhD, hematologic oncologist, associate attending physician, Memorial Sloan Kettering Cancer Center.
Read More
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Dr Raajit Rampal Discusses Disease Modification and Emerging Therapies in Polycythemia Vera
April 7th 2024Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the potential of a disease-modifying therapy in polycythemia vera, treating high-risk vs low-risk patients, and emerging therapies in the pipeline.
Read More
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
Indirect Comparison Finds Bimekizumab More Effective Than Guselkumab in Psoriatic Arthritis
April 4th 2024Patients included in the analysis had psoriatic arthritis and had either not been treated with biologic disease-modifying antirheumatic drugs or had an inadequate response or an intolerance to tumor necrosis factor inhibitors.
Read More
Emerging Data Continue to Evolve Treatment Utilization in MPNs
April 1st 2024Despite being used for decades, there continues to be emerging data on interferons and how they should be used in patients with myeloproliferative neoplasms (MPNs), explains Raajit Rampal, MD, PhD, hematologic oncologist, associate attending physician, Memorial Sloan Kettering Cancer Center.
Read More
Dr Raajit Rampal Highlights Emerging Therapies in MPNs
March 22nd 2024Interferons have been a major treatment for myeloproliferative neoplasms (MPNs) for decades, but emerging therapies are expanding the treatment armamentarium, explained Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center.
Read More
Covered Preventive Services at Risk: V-BID Summit Breaks Down the Braidwood v Becerra Case
March 20th 2024For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
Read More
It is possible, if you lay the groundwork, to provide patients with acute leukemias with aggressive and effective therapies, while still allowing them to maintain quality of life, explained Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.
Read More
Disease-, Age-, Genomic-Specific Factors Increase Risk of ET, PV, PrePMF Developing Into Overt MF
March 16th 2024New research highlights the factors that increase the likelihood that essential thrombocytopenia (ET), polycythemia vera (PV), and prefibrotic primary myelofibrosis (PrePMF) will evolve into overt myelofibrosis (MF).
Read More
FDA Approves Resmetirom, First Treatment for NASH With Liver Fibrosis
March 14th 2024The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.
Read More
Evolution of HDHPs With VBID Components Can Improve Care for Chronic Disease
March 14th 2024Over the course of the last 20 years, high-deductible health plans (HDHPs) have undergone an evolution. Today’s plans, with more high-value services covered predeductible, can improve care for people with chronic diseases, said panelists at the 2024 Value-Based Insurance Design (V-BID) Summit.
Read More
Patients With MPNs Have Increased Risk of Thrombosis, Hemorrhage, Leukemic Transformation
March 13th 2024Compared with matched controls, patients with myeloproliferative neoplasms (MPNs) had a higher risk of developing thrombosis, hemorrhage, and leukemic transformation, according to a longitudinal cohort study.
Read More
Dr Jennifer Vaughn: Patients With MPN, MDS Should Discuss Long-Term Priorities Upfront
March 1st 2024For many patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS), their disease will be chronic, giving them a long-term cancer experience, said Jennifer Vaughn, MD, of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital.
Read More
PROs May Successfully Risk Stratify Patients With Cutaneous Chronic GVHD
March 1st 2024Two existing, well-validated patient-reported outcome (PRO) measures may be useful as a prognostic marker for mortality and assist with treatment selection for patients with cutaneous chronic graft-vs-host disease (GVHD).
Read More
Primary Care Delivery Is in Urgent Need of Innovation
February 28th 2024At an Institute for Value-Based Medicine® event cohosted by The American Journal of Managed Care® and Optum, speakers emphasized that innovation is urgently needed in primary care delivery to address the broken US health care system.
Read More
Venetoclax Plus HMA Therapy Shows Encouraging Results in Higher-Risk MDS/CMML
February 22nd 2024Results of a phase 1/2 trial show encouraging outcomes for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) treated with the fully oral regimen of venetoclax and decitabine plus cedazuridine.
Read More
FDA Accepts BLA for Datopotamab Deruxtecan for Nonsquamous NSCLC
February 19th 2024The application is based on results of the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan in nonsquamous non–small cell lung cancer (NSCLC), first presented at the 2023 European Society for Medical Oncology Congress.
Read More